Formaldehyde → 2-(1-methyl-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile
反応式
Cl.[CH3:2][N:3]1[CH:7]=[C:6]([C:8]2[N:13]=[C:12]([C:14]3[CH:15]=[N:16][N:17]([C:19]4([CH2:25][C:26]#[N:27])[CH2:24][CH2:23][NH:22][CH2:21][CH2:20]4)[CH:18]=3)[N:11]3[CH:28]=[CH:29][N:30]=[C:10]3[CH:9]=2)[CH:5]=[N:4]1.[C:31](#N)C.C(N(CC)CC)C.C=O.[BH-](OC(C)=O)(OC(C)=O)OC(C)=O.[Na+]>C(=O)(O)[O-].[Na+].CCOC(C)=O>[CH3:31][N:22]1[CH2:21][CH2:20][C:19]([CH2:25][C:26]#[N:27])([N:17]2[CH:18]=[C:14]([C:12]3[N:11]4[CH:28]=[CH:29][N:30]=[C:10]4[CH:9]=[C:8]([C:6]4[CH:5]=[N:4][N:3]([CH3:2])[CH:7]=4)[N:13]=3)[CH:15]=[N:16]2)[CH2:24][CH2:23]1参加物
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
2-(4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile hydrochloride (15.8 mg, 0.0318 mmol) was suspended in acetonitrile (318 μL, 0.0318 mmol). To this was added triethylamine (17.7 μL, 0.127 mmol) to freebase, followed by formaldehyde (25.8 mg, 0.318 mmol). After 30 minutes, NaBH(OAc)3 (33.7 mg, 0.159 mmol) was added. After stirring for 30 minutes, the reaction mixture was diluted in saturated sodium bicarbonate and EtOAc. The aqueous layer was back-extracted with DCM. The combined organic layer was washed with brine, dried with MgSO4, filtered and concentrated. Purification of the resulting crude material by reverse phase HPLC using a 0-100% acetonitrile/water gradient afforded 2-(1-methyl-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile (2.0 mg, 16% yield). MS (apci) m/z=402.1 (M+H).
後処理
- extractionThe aqueous layer was back-extracted with DCM
- washThe combined organic layer was washed with brine
- dry with materialdried with MgSO4
- filtrationfiltered
- concentrationconcentrated
- customPurification of the resulting crude material by reverse phase HPLC
出典と根拠
- ORDレコード
- ord-52fc0dea71ce4a2aa92f41adeff8f4d9
- 出典データセット
- uspto-grants-2015_02
- 特許番号
- US08962596B2
反応ノート
読み込み中…